References

1. 1.
   CERSOSIMO R J. Lung cancer：A review［J］.Am J Health Syst Pharm，2002，59（7）：611-642.
2. 2.
   CHEN P X， LIU Y H， WEN Y K，et al.Non-small cell lung cancer in China［J］.Cancer Commun，2022，42（10）：937-970.
3. 3.
   PARSONS A， DALEY A， BEGH R，et al.Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis： Systematic review of observational studies with meta-analysis［J］.BMJ，2010， doi： .
4. 4.
   HAN B，ZHENG R，ZENG H，et al.Cancer incidence and mortality in China，2022［J］.J Natl Cancer Cent，2024，4（1）：47-53.
5. 5.
   ALLEMANI C， MATSUDA T， CARLO V， et al.Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）： Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries［J］.Lancet，2018，391（10125）：1023-1075.
6. 6.
   WANG X L ，YUAN F ，WU X N，et al.Characteristics and clinical significance of immune cells in tumor microenvironment of non-small cell lung cancer［J］.J Clin Pulm Med，2020，25（7）：1021-1026，1036.
7. 7.
   MA T X，LI J T，LIANG J Q，et al.Clinical observation on 30 cases of small cell lung cancer with deficiency of both Qi and Yin syndrome in the limited-stage treated by Guiqi Yiyuan Gao（归芪益元膏） combined with chemotherapy［J］.J Gansu Univ Chin Med，2022，39（1）：42-46.
8. 8.
   DU S G，LI J T，LIANG J Q，et al.Clinical observation on 60 cases of lung adenocarcinoma with deficiency of both qi and yin syndrome in advanced stage treated by Guiqi Yiyuan Gao（归芪益元膏） combined with gefitinib tablets and radiotherapy［J］.J Gansu Univ Chin Med，2021，38（3）：51-55.
9. 9.
   RECK M，CARBONE D P，GARASSINO M，et al.Targeting KRAS in non-small-cell lung cancer：Recent progress and new approaches［J］.Ann Oncol，2021，32（9）：1101-1110.
10. 10.
    GAO Z，CHEN J F，LI X G，et al.KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma［J］.Cancer Cell Int，2022，22（1）：128.
11. 11.
    AVERY T Y， KÖHLER N， ZEISER R，et al.Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation［J］.Front Oncol，2022， doi：.
12. 12.
    XIA H，GREEN D R， ZOU W.Autophagy in tumour immunity and therapy［J］.Nat Rev Cancer，2021，21（5）：281-297.
13. 13.
    WANG X，WU W K K，GAO J，et al.Autophagy inhibition enhances PD-L1 expression in gastric cancer［J］.J Exp Clin Cancer Res，2019，38（1）：140.
14. 14.
    GAO Z， CHEN J F， LI X G，et al.KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma［J］.Cancer Cell Int，2022，22（1）：128.
15. 15.
    XIA J，DAI L，WANG L，et al.Ganoderic acid DM induces autophagic apoptosis in non-small cell lung cancer cells by inhibiting PI3K/Akt/mTOR activity［J］.Chem Biol Interact，2020， doi：.
16. 16.
    REAGAN-SHAW S， NIHAL M，AHMAD N.Dose translation from animal to human studies revisited［J］.FASEB J，2008，22（3）：659-661.
17. 17.
    DE SAUVAGE M A，TORRINI C，NIEBLAS-BEDOLLA E，et al.The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis［J］.Neuro Oncol， 2024，26（5）：889-901.
18. 18.
    TIAN P Y，YU H Y，LI X，et al.Astragali Radix-Curcumae Rhizoma inhibits metastasis of lewis lung cancer in mice via C5a/NETs pathway［J］.Chin J Exp Tradit Med Form，2024，30（14）：27-36.
19. 19.
    WANG Y Y， YAN S Y.Practical TCM Internal Medicine［M］.Version 2.Shanghai：Shanghai Science and Technology Press，2009：671-672.
20. 20.
    ZHANG C N，LI J T，LIU Y Q，et al.Influence of Guiqi Yiyuangao on expression of cytochrome-C and Bax， Bcl-2 during damage caused by heavy ion radiation induced bystander effect in vivo［J］. Chin J Exp Tradit Med Form，2017，23（14）：121-127.
21. 21.
    ZHANG C N，LI J T，LIU Y Q， et al.Effects of Guiqi Yiyuan ointment on Bax， Bcl-2 and peripheral hemogram of rats damaged by heavy ion radiation induced bystander effects［J］. China J Tradit Chin Med Pharm，2018，33（1）：333-336.
22. 22.
    LIANG J Q，LI J T，LI J，et al.Effects of lung and kidney bystander effect of Guiqi Yiyuan ointment on rat with radiation damage by 12C6+ beam based on transcriptome［J］. China J Tradit Chin Med Pharm，2019，34（5）：2130-2134.
23. 23.
    LEE H J，VENKATARAME GOWDA SARALAMMA V，KIM S M，et al.Pectolinarigenin induced cell cycle arrest， autophagy， and apoptosis in gastric cancer cell via PI3K/Akt/mTOR signaling pathway［J］.Nutrients， 2018，10（8）：1043.
24. 24.
    YOU L，WANG Z，LI H，et al.The role of STAT3 in autophagy［J］.Autophagy，2015，11（5）：729-739.
25. 25.
    SEO S U，WOO S M，LEE H S，et al.mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy［J］.Oncogene，2018，37（38）：5205-5220.
26. 26.
    LIU Z， ZHAO K，WEI S，et al.ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer［J］.Oncoimmunology，2020，9（1）：1758003.
27. 27.
    CHEN N，FANG W，LIN Z，et al.KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma［J］.Cancer Immunol Immunother，2017，66（9）：1175-1187.
28. 28.
    KINSEY C G，CAMOLOTTO S A，BOESPFUG A M，et al.Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers［J］.Nat Med，2019，25（4）：620-627.